[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367253-105":59,"doc-detail-367253-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","immune-checkpoint-blockade-delays-cancer-development-and-extends-survival-in-dna-polymerase-mutator-syndromes","Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes","","Immune checkpoint blockade (ICB) improves outcomes for several cancers, but responses remain limited due to incomplete biomarker guidance. This study investigates how high tumor mutation burden (TMB) generated by DNA polymerase mutator mutations influences tumor biology and immunotherapy response. Mice engineered with germline and conditional exonuclease-domain mutations in Pold1 and Pole develop spontaneous, tissue type–dependent cancers with variable increases in TMB and mutation signatures linked to POLD1/POLE alterations. Despite elevated TMB, only a subset of established tumors responds to ICB, and survival benefits are not improved when mutator alleles are introduced into specific lung cancer models. Tumor-cell passaging without immune editing reveals in vivo antigenic elimination and rejection in immunocompetent hosts. Importantly, earlier ICB treatment before observable tumors delays cancer onset, improves survival, and selects against aneuploidy, supporting ICB as a potential cancer prevention strategy for high-risk individuals.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/immune-checkpoint-blockade-delays-cancer-development-and-extends-survival-in-dna-polymerase-mutator-syndromes/367253/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/immune-checkpoint-blockade-delays-cancer-development-and-extends-survival-in-dna-polymerase-mutator-syndromes/367253.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are current biomarkers insufficient for predicting immune checkpoint blockade response?","Question",{"text":112,"@type":113},"Only a subset of patients respond to ICB, and clear, reliable biomarkers are lacking. Existing biomarkers include high TMB, elevated PD-L1/PD-1 expression, and tumor-immune infiltration, yet not all high-TMB tumors respond.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were DNA polymerase mutator syndromes modeled to test ICB effectiveness?",{"text":117,"@type":113},"The study generated mice with germline and conditional mutations in the exonuclease domains of Pold1 and Pole, producing spontaneous cancers with tissue-dependent increases in TMB and human-relevant mutational signatures.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find about ICB timing and cancer prevention?",{"text":121,"@type":113},"ICB given earlier, before observable tumors develop, delayed cancer onset and improved survival. It also selected for tumors without aneuploidy, suggesting potential for cancer prevention in high-risk individuals.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367253,1790523659,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes  \nAkshada Sawant1,2, Fuqian Shi1, Eduardo Cararo Lopes1, Zhixian Hu1,2, Somer Abdelfattah1, Jennele Baul1, Jesse R. Powers1,2, Christian S. Hinrichs1, Joshua D. Rabinowitz2, Chang S. Chan1,3, Edmund C. Lattime1,3, Shridar Ganesan1,3, and Eileen P. White1,2,4  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Mutations in the exonuclease domains of the replicative nuclear DNA polymerases POLD1 and POLE are associated with increased cancer incidence, elevated tumor mutation burden (TMB), and enhanced response to immune checkpoint blockade (ICB). Although ICB is approved for treatment of several cancers, not all tumors with elevated TMB respond, highlighting the need for a better understanding of how TMB affects tumor biology and subsequently immunotherapy response. To address this, we generated mice with germline and conditional mutations in the exonuclease domains of Pold1 and Pole. Engineered mice with Pold1 and Pole mutator alleles presented with spontaneous cancers, primarily lymphomas, lung cancer, and intestinal tumors, whereas Pold1 mutant mice also developed tail skin carcinomas. These cancers had highly variable tissue type–dependent increased TMB with mutational signatures associated with POLD1 and POLE mutations found in human cancers. The Pold1 mutant tail tumors displayed increased TMB; however, only a subset of established tumors responded to ICB. Similarly, introducing the mutator alleles into mice with lung cancer driven by mutant Kras and Trp53 deletion did not improve survival, whereas passaging these tumor cells in vitro without immune editing and subsequently implanting them into immunocompetent mice caused tumor rejection in vivo. These results demonstrated the efficiency by which cells\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | with antigenic mutations are eliminated in vivo. Finally, ICB treatment of mutator mice earlier, before observable tumors had developed delayed cancer onset, improved survival and selected for tumors without aneuploidy, suggesting the potential of ICB in highrisk individuals for cancer prevention.\u003Cbr>Significance: Treating high-mutation burden mice with immunotherapy prior to cancer onset significantly improves survival, raising the possibility of utilizing immune checkpoint blockade for cancer prevention, especially in individuals with increased risk.\u003Cbr>\u003Cbr>Created in BioRender. Sawant, A. (2024) [https://BioRender.com/z50t811](https://BioRender.com/z50t811) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nImmune checkpoint blockade (ICB) has provided an extraordinary advance in the treatment of multiple cancer types (1). ICB involves the use of antibodies that target T cell coreceptors such as PD-1, PD-L1, and cytotoxic T-lymphocyte–associated protein 4 (2, 3). ICB has been approved for use as a first-","cbCais7j065aioIJ","https://ap.wps.com/l/cbCais7j065aioIJ","pdf",9666538,15,"English","# Introduction\n## Immune checkpoint blockade and response variability\n## Biomarkers and the role of tumor mutation burden\n## Rationale based on DNA polymerase and mismatch repair defects","[{\"question\":\"Why are current biomarkers insufficient for predicting immune checkpoint blockade response?\",\"answer\":\"Only a subset of patients respond to ICB, and clear, reliable biomarkers are lacking. Existing biomarkers include high TMB, elevated PD-L1/PD-1 expression, and tumor-immune infiltration, yet not all high-TMB tumors respond.\"},{\"question\":\"How were DNA polymerase mutator syndromes modeled to test ICB effectiveness?\",\"answer\":\"The study generated mice with germline and conditional mutations in the exonuclease domains of Pold1 and Pole, producing spontaneous cancers with tissue-dependent increases in TMB and human-relevant mutational signatures.\"},{\"question\":\"What did the study find about ICB timing and cancer prevention?\",\"answer\":\"ICB given earlier, before observable tumors develop, delayed cancer onset and improved survival. It also selected for tumors without aneuploidy, suggesting potential for cancer prevention in high-risk individuals.\"}]","Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes | PDF",1790169915,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/797171c0c6f9a1e8620112d148d3653d.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/312ec84b84d1eaebfe46424d0bc301d8.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d92baab8b7cffd76c76e59781c2df0e6.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c31ebe78842bbeab528b618972553792.webp",980,1311]